OBJECTIVES: To describe the experience with upper gastrointestinal (GI) symptoms, the impact of symptoms on daily life, and nonadherence and discontinuation of lowdose acetylsalicylic acid (ASA) treatment in patients with cardiovascular (CV) risk. METHODS: Twenty-two patients from the US were selected to undergo face-to-face, 1-hour qualitative interviews following a multicentre 3-month observational study of patients 18 years at risk of or with CV disease, about to begin or previously prescribed daily low-dose ASA (75-325 mg) within 5 years (ClinicalTrials.gov identifier: NCT00681759; AstraZeneca study code: D961FC00004). Interviewee-selection was based on low-dose ASA history, CV risk, GI medication use, and the occurrence of 1 upper GI event during the study period. Interviews were semi-structured and were audio-recorded and transcribed for analysis. RESULTS: 16 interviews were evaluable (mean age 44.7 years; 68.8% women); 6 patients were excluded following technical failure or violation of inclusion/exclusion criteria. Commonly reported upper GI symptoms were: burning feeling behind the breastbone (n 9); burning feeling in the upper stomach (n 4); acid taste in the mouth (n 4); regurgitation (n 4). Upper GI symptoms negatively impacted aspects of patients' lives, including: food intake (n 12); sleep quality (n 6); emotions (n 5). Most patients reported occasional over-the-counter medication use; many altered their diet to manage upper GI symptoms. Overall, five patients reported treatment nonadherence. Upper GI symptoms caused nonadherence in 3 patients; 2 missed doses when GI symptoms were severe, despite being aware of low-dose ASA benefits. Patients who understand the purpose of their low-dose ASA prescription could articulate the importance of adherence and the intention to continue therapy. CONCLUSIONS: Patients who understand the purpose of low-dose ASA treatment are more likely to adhere to therapy, although doses may be intentionally missed due to upper GI symptoms.
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HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERCHOLESTEROLEMIA
Müller-Nordhorn J 1 , Englert H 2 , Wegscheider K 3 , Berger H 4 , Völler H 5 , Katus HA 6 , Willich SN 1 1 Charité University Medical Center, Berlin, Germany, 2 University of Applied Sciences, Münster, Germany, 3 Department of Medical Biometry and Epidemiology, Hamburg, Germany, 4 University of Applied Sciences, Osnabrück, Germany, 5 Klinik am See, Rüdersdorf, Germany, 6 Department of Cardiology, Heidelberg, Germany OBJECTIVES: In patients with chronic diseases such as hypercholesterolemia, healthrelated quality of life (HRQoL) is an important outcome. The objective of the present study was to determine factors associated with an impaired HRQoL after 12 months. METHODS: Patients with hypercholesterolemia were prospectively included in the ORBITAL (Open-label primary care study: Rosuvastatin-Based compliance Initiatives linked To Achievement of LDL goals) Study. Inclusion criteria were hypercholesterolemia with an indication for statin therapy according to the European Guidelines. Follow-up was 12 months. A total of 1961 primary care practices in Germany participated. HRQoL was assessed with the Short Form (SF)-12 health status instrument. RESULTS: Of the 7640 patients included, 47% were high-risk patients in the primary prevention of coronary heart disease, 42% were patients with coronary heart disease, and 11% did not have a priori risk stratification. Physical SF-12 summary scores were inversely associated with risk stratum, however, there was no such association between mental SF-12 summary scores and risk stratum. An impaired physical SF-12 score was associated with increased age, lower educational level, higher body mass index, smoking, existing coronary heart disease, a history of stroke, or a clinical event during follow-up. An impaired mental SF-12 score was associated with younger age, hypertension, or a clinical event during follow-up. CONCLUSIONS: HRQoL in patients with hypercholesterolemia is associated with socioeconomic factors, lifestyle, and clinical events. Effective prevention is thus not only essential for clinical outcome but also for the maintenance of HRQoL in patients with hypercholesterolemia. ClinicalTrials.gov Identifier: NCT00379249.
PCV149 149 ASSESSMENT OF QUALITY OF LIFE AMONG PATIENTS WITH HYPERTENSION AND DIABETES TYPE 2
Turska W, Skowron A Jagiellonian University Collegium Medicum, Cracow, Poland OBJECTIVES: The assessment of quality of life among ambulatory patients with hypertension (HTN), diabetes type 2 (DM2) or coexisting HTN and DM2 (HTN DM2). METHODS: Patients of 4 ambulatory care setting in Cracow (Poland) with HTN, DM2 or HTN DM2 were included. Polish versions of SF-36v.2 and EQ-5D were used with the supplementary questions about age, gender, education, body mass, place of residence. Student's t-test was used to compare the differences between paired groups. RESULTS: A total of 135 patients were included (68 with HTN, 22 with DM2, 45 with HTN DM2); 57,8% of patients were women. 31,11% of patients with HTN DM2, 36,77% of patients with HTN and 72,73% of patients with DM2 assessed their health status as well, none indicated the answer excellent or very good. Usually women indicated their QOL lower than men (HTN: PF, RP, PCS p 0,05; HTN DM2: PF, PB p 0,05). PCS was rated lower or similar to MCS; HTN: PCS 39, 30 7, 88, MCS 40, 45 10, 96, DM2: PCS 42, 77 8, 22, MCS 42, 23 9, 86; HTN DM2: PCS 38, 89 9, 05, MCS 42, 66 10, 66 . Due to EQ-5D 80% of patients had no problems with self care and 60% -with usual activities. Over 85% of patients had moderate or extreme pain or discomfort, more than 70% of patients felt moderately or extremely anxious or depressed. About 75% of patients with HTN and HTN DM2 confirmed problems with walking around. On VAS scale, patients with HTN, DM2 and HTN DM2 assessed their health state accordingly: 54,87 15,70, 59,14 21,06, 55,56 14,50, with no statistically significant differences between diseases and sexes. CONCLUSIONS: Patients with HTN and HTN DM2 estimated their quality of life lower than patients with DM2.
PCV150 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH METABOLIC SYNDROME: A COMPARISON OF THE UNITED STATES, EUROPE, AND JAPAN
Wagner S 1 , Fukuda T 2 , Nagae T 3 , Gupta S 1 , DiBonaventura M 1 , Stankus AP 1 1 Consumer Health Sciences International, Princeton, NJ, USA, 2 University of Tokyo, Bunkyo, Tokyo, Japan, 3 York Pharma KK, Tokyo, Japan OBJECTIVES: To investigate the differences in work productivity in patients with metabolic syndrome across three geographies. METHODS: Data from the 2008 National Health and Wellness Survey (NHWS), an annual internet survey of attitudes, behaviors, health status, and outcomes of adults in the US, EU (Germany, Spain, Italy, UK, and France), and Japan (JPN) were used for the analysis. Metabolic syndrome was defined as having at least three of the following: diabetes, BMI 30, high cholesterol, or hypertension. Multiple regressions were used to determine the effect of geography on work productivity using the validated Work Productivity and Activity Impairment Questionnaire (WPAI) controlling for age, gender and total number of comorbidities. RESULTS: Of the 3,995 employed patients with metabolic syndrome in the analysis 881 (22.1%) were from Europe, 89 (2.2%) from JPN, and 3,025 (75.7%) from the US. EU patients (10.9%) had significantly higher levels of percent work missed in the past week due to health (absenteeism) than US (6.2%) and JPN (5.3%) patients. No significant differences amongst geographies were seen for percent impairment at work (presenteeism), however, EU patients had higher levels of percent overall work impairment compared to US patients (p 0.05). For all metabolic patients (n 11,131) activity impairment was significantly lower for JPN compared with US and EU (p 0.05). After controlling for age, gender and number of comorbid conditions, the differences remained significant, with EU having higher absenteeism, overall work impairment, and activity impairment than the US, and JPN reporting less activity impairment than the US (p 0.05). CONCLUSIONS: The effect of metabolic syndrome on work productivity differed significantly across the three geographies. Any combination of factors may explain these differences: awareness of the condition, treatment differences, cultural issues, and health systems, amongst other. Further research is needed to describe the impact metabolic syndrome may have globally.
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REVIEW OF STUDIES EVALUATING THE IMPACT OF POLICY-DRIVEN STATIN SWITCH PROGRAMS ON PATIENTS
Folia C 1 , Liovas A 2 1 Agro Health Associates Inc., Burlington, ON, Canada, 2 AstraZeneca Canada Inc, Mississauga, ON, Canada OBJECTIVES: Although cardiovascular disease remains a major cause of death and morbidity in western countries, statins are well recognized for their role in prevention. The on-going need to maintain cost-effective health care has led to greater use of policy-driven therapeutic substitution programs for statins; however the impact of these policies on patients is often under-reported. METHODS: A review of published literature describing the impact of policy-driven statin switch programs was conducted based on a MEDLINE search [using the following terms: Hydroxymethylglutaryl-CoA Reductase Inhibitors (MeSH), and statin, switch, interchange, substitute, substitution (all fields); limited to English language and 1989-2009] and a review of reference lists from selected papers. RESULTS: Twenty-three studies were identified. Seventeen studies evaluated the impact of a "switch down" to equal or less potent statins. 6 studies evaluated the impact of a "switch up" to more potent statins. Following introduction of "switch down" programs, 23-47% of patients were not eligible or willing to switch (7 studies), 17-38% of patients were switched to a non-equivalent (lower) dose of the new statin (3 studies), 4-11% of patients switched back to their original statin (5 studies), and switched patients were 19-33% less likely to be adherent to therapy compared to those with no switch. Persistence was significantly reduced among switch patients (2 studies). No significant trend in lipid levels was noted (12 studies) but loss of target levels was reported in 7-20% of patients (2 studies) and 3 studies reported an increase in vascular events or death after switching. Studies evaluating "switch up" programs consistently demonstrated improved reductions in lipid
